Tag: Valneva
Valneva Completes Submission of Marketing Authorization Application to the FDA for its Chikungunya Vaccine Candidate
By Claude Leguilloux Published on 23/12/2022 at 07:55 Photo credit © Valneva (Boursier.com)…
Valneva: marketing authorization dossier in chikungunya submitted to the FDA – 23/12/2022 at 07:43
(CercleFinance.com) – Valneva announces that it has completed the submission of its marketing authorization application (MA) to the US FDA, for its single-injection vaccine candidate against chikungunya, VLA1553, in people…
Valneva: an appointment without major announcement
By Jean-Baptiste Andre Published on 07/12/2022 at 2:20 p.m. Second day of fairly sharp decline (-3.5% to 6.5 euros) for Valneva after an R&D…
Valneva: an investor day organized in New York – 06/12/2022 at 11:07
(CercleFinance.com) – Valneva said on Tuesday it expects “substantial” growth in its business over the next 12 to 36 months with the potential commercialization of two new vaccines. During an…
Valneva: positive data from a chikungunya vaccine
(CercleFinance.com) – Valneva, a vaccine company, today announced positive antibody persistence data twelve months after vaccination with a single dose of its chikungunya vaccine candidate, VLA1553. Following the announcement of…
Valneva: Positive Data from a Chikungunya Vaccine
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Valneva: encouraging data on Lyme vaccine – 01/12/2022 at 09:40
(CercleFinance.com) – Valneva and Pfizer on Thursday unveiled new data at six months on the persistence of antibodies in children and adults vaccinated with their candidate against Lyme disease. These…
Valneva: sharp reduction in nine-month losses – 11/10/2022 at 09:20
A Valneva laboratory (photo credit: Valneva Group / ) (CercleFinance.com) – Valneva posted an adjusted net loss of 99.1 million euros for the first nine months of 2022, compared to…
Valneva reduces its loss and launches a savings plan – 11/10/2022 at 10:08
(AOF) – Valneva, a biotechnology company, reduced its net loss over nine months. Over the period from January to September 2022, this amounted to 99.1 million euros against a net…
Valneva promotes its single-shot chikungunya vaccine candidate internationally – 10/10/2022 at 17:08
(AOF) – Valneva, a vaccine company, today announced that it will be presenting on its single-shot chikungunya vaccine candidate during the fourth quarter of 2022 at several leading scientific conferences,…
Valneva: The Grimaud family falls below 20% of the votes
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Valneva: series of presentations planned in the chikungunya – 10/10/2022 at 07:43
(CercleFinance.com) – Valneva announces that it will make presentations on its single-shot chikungunya vaccine candidate during the fourth quarter of 2022 at several leading scientific conferences. The vaccine company will…